A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer

Annals of Oncology

Volumn 21, Issue 2, 2010, Pages 305-311

  Michels, J ^a   Ellard, S L ^a   Le, L ^a   Kollmannsberger, C ^a   Murray, N ^a   Tomlinson Guns, E S ^b   Carr, R ^c   Chi, K N ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c ABBOTT LABORATORIES   (United States)

Author keywords

Abt 751; Chemotherapy; Docetaxel; Prostate cancer

Indexed keywords

DOCETAXEL; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; ANTINEOPLASTIC AGENT; SULFONAMIDE; TAXOID;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONSTIPATION; DEHYDRATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DYSPNEA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; HEARTBURN; HUMAN; HYPOKALEMIA; INFECTION; INSOMNIA; LACRIMATION DISORDER; LEUKOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MOOD DISORDER; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHINITIS; SENSORY NEUROPATHY; SYNCOPE; TASTE DISORDER; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; VEIN THROMBOSIS; VOMITING; XEROSTOMIA; ADJUVANT CHEMOTHERAPY; CASTRATION; CLINICAL TRIAL; DISEASE COURSE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSTATE TUMOR; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASTRATION; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; SULFONAMIDES; TAXOIDS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 77951907080     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp311     Document Type: Article

References (18)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
2. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
3. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520.
4. Petrylak DP, Ankerst DP, Jiang CS et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 2006; 98: 516-521.
5. Armstrong AJ, Garrett-Mayer E, Ou Yang YC et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 2007; 25: 3965-3970.
6. Jorgensen TJ, Tian H, Joseph IB et al. Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth. Cancer Chemother Pharmacol 2007; 59: 725-732.
7. Segreti JA, Polakowski JS, Koch KA et al. Tumor selective antivascular effects of the novel antimitotic compound ABT-751: an in vivo rat regional hemodynamic study. Cancer Chemother Pharmacol 2004; 54: 273-281.
8. Yee KW, Hagey A, Verstovsek S et al. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2005; 11: 6615-6624.
9. George DJ, Halabi S, Shepard TF et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001; 7: 1932-1936.
10. Frost DJ, Refici ML, Joseph IB et al. ABT-751, an oral antimitotic, shows additive and synergistic activity with docetaxel in preclinical models. Proc Am Assoc Cancer Res Annu Meet 2007; 48: 338.
11. Hande KR, Hagey A, Berlin J et al. The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Clin Cancer Res 2006; 12: 2834-2840.
12. Fox E, Maris JM, Widemann BC et al. A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors. Clin Cancer Res 2008; 14: 1111-1115.
13. Bubley GJ, Carducci M, Dahut W et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17: 3461-3467.
14. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
15. Cooney MM, van Heeckeren W, Bhakta S et al. Drug insight: vascular disrupting agents and angiogenesis-novel approaches for drug delivery. Nat Clin Pract Oncol 2006; 3: 682-692.
16. Bruno R, Hille D, Riva A et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998; 16: 187-196.
17. ten Tije AJ, Verweij J, Carducci MA et al. Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. J Clin Oncol 2005; 23: 1070-1077.
18. Chi KN, Siu LL, Hirte H et al. A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res 2008; 14: 833-839.